CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. It provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

CordenPharma

biosyn Arzneimittel GmbH is involved in the pharmaceutical and biotech sectors, specializing in trace elements, particularly high-dose selenium injections, and operates unique GMP-active ingredient manufacturing plants.

biosyn Arzneimittel GmbH

P-BIO is a private non-profit association that brings together companies linked to the biotechnology and life sciences sector in Portugal.

P-BIO

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products.

Visit to learn more > cordenpharma.com

Corden Pharma - A Full-Service CDMO

CordenPharma is honored to have been chosen by Cereno Scientific as the CDMO partner in the manufacturing of CS1. We join them in their commitment to helping patients with the rare disease PAH.

#CordenPharma #cerenoscientific #pah #pharmaceuticals 

https://lnkd.in/gYgVcfAg

Congratulations John Cameron on your promotion as Director, Global Injectables Platform, CordenPharma International.
 
All the best in this exciting new role!
 
#CordenPharma #CDMO #injectables #drugproducts #pharmaceuticalindustry

End of December CordenPharma’s Leadership Team met for our General Management Meeting in the Basel area, Switzerland. A series of dynamic and interactive sessions & workshops adressed key topics such as Global Quality & Compliance, Procurement, Global IT Infrastructure and Communications. This was a unique opportunity for us to exchange, collaborate and close another successful year together. 

#cordenpharma #leadership #cdmo #exchange #together

> Press Release 4 January 2024 - Basel / Providence> CordenPharma & pHLIP Announce Strategic Alliance to Develop pHLIP® LNP Targeted Delivery Platform for RNA & Gene Therapies. 

CordenPharma and pHLIP, Inc. are pleased to announce their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics. The alliance will combine CordenPharma’s proprietary Lipid NanoParticle (LNP) technology and GMP manufacturing expertise with pHLIP’s proprietary pH (Low) Insertion Peptide (pHLIP®) targeted delivery technology and drug development expertise to formulate (pHLIP®) coated LNPs for use by biopharmaceutical companies seeking to deliver mRNA-based and gene therapy payloads. Such payloads can be used to treat cancer, inflammation, and genetic diseases, or employ mRNA strategies for vaccination. The companies believe that their novel pHLIP-LNP platform will greatly enhance the commercial viability and success of many pioneering RNA, DNA and CRISPR therapies. The alliance will also enable CordenPharma and pHLIP to collaborate in developing and manufacturing small molecule drug payloads directly conjugated with (pHLIP®) peptides for biopharmaceutical companies seeking to selectively target their small molecular payloads into cells in acidic diseased tissues. CordenPharma serves as the CDMO supplier in the GMP manufacture of pHLIP® peptides and (pHLIP®) drug conjugates, and the new alliance further builds upon their collaborative efforts in this important field.

Dr. Michael Quirmbach, CordenPharma CEO & President, commented “CordenPharma is proud to participate in this alliance with pHLIP, as it represents a great synergy of cutting-edge technology and lipid, peptide, conjugate and LNP expertise which brings a potentially game-changing delivery platform to the LNP-based drug development field. Our collaboration allows access to effective, precisely targeted LNP delivery of RNA, DNA, and gene therapy payloads across various important therapeutic indications, with an ultimately profound effect on saving the lives of patients.”

Dr. Yana Reshetnyak, pHLIP Co-Founder, CEO & President, stated "I am very excited about the potential scientific, medical and commercial benefits of the pHLIP-LNP delivery platform to address large unmet medical needs in the field of RNA and gene therapies. pHLIP® peptides insert across the membranes of acidic cells, including cancer cells, activated macrophages and fibroblasts, to deliver drugs directly into the cytoplasm. pHLIP® drug conjugates are now in clinical trials. CordenPharma's expertise in formulating and manufacturing LNPs and pHLIP® peptides makes them our ideal partner for this important venture."

Read full PR > https://lnkd.in/ezyZrTmW

#CordenPharma #lipids #lnp #rna #genetherapy #mrna #peptides #pharmaceuticals #dna #drugdelivery

Happy Holidays!
Thank you for your trust in choosing CordenPharma as your CDMO partner. We value the opportunity to work together towards improving the lives of patients.
 
We look forward to future collaboration and wish you a prosperous and healthy 2024.
 
 https://lnkd.in/eSQRJ-ak

Congratulations on your well-deserved retirement Juerg Burger!
 
 Thank you for your great leadership, you have been instrumental on the development and growth of CordenPharma Liestal.
 
 #CordenPharma #CDMO #thankyou #leadership #pharmaceuticalindustry #drugproducts #apis

> European Pharmaceutical Manufacturer's CPHI Roundtable features CEO Michael Quirmbach

“Over the past year, CordenPharma has achieved remarkable milestones in the pharmaceutical and biotech industry. The company’s involvement in launching innovative medicines for both orphan diseases and larger conditions showcases our commitment to making a significant impact on patients’ lives. The excitement about our products and innovations is evident, with substantial investments in expanding our capabilities.

Our ambitious €500 Million CapEx expansion program over the next three years, especially in key areas such as Lipid NanoParticle (LNP) formulation, specialized lipid excipients, sterile injectables and new offerings for highly potent & oncology Oral Solid Dosage (OSD) manufacturing, is setting the stage for continued growth to meet the market demand in those important areas.

Key takeaways on the agenda at CPHI Barcelona 2023 included supply chain resilience and diversification, which are critically important topics for our customers. As we look ahead to 2024, our commitment to innovation, sustainability, and customer-centric solutions will continue to drive our success in the pharmaceutical industry.”

https://lnkd.in/eZTwS7ib

#CordenPharma #cphibarcelona2023 #apis #drugproduct #cdmo #lipids #peptides #lnps #injectables #oralsoliddose #osd #pharmaceuticals #pharmaceuticalmanufacturing

Making a Difference: Our Commitment to Society – A Journey Begins.
 
We are delighted to share the beginning of our journey on corporate responsibility at CordenPharma. It’s a story of commitment and collaboration that showcases our passion for being active and at the same time helping those less gifted. The KMSK CordenPharma Team Challenge was a unique opportunity for us to extend our support of the Swiss Association for Children with rare diseases, "Förderverein für Kinder mit seltenen Krankheiten – KMSK" https://www.kmsk.ch/.

It was an opportunity not just to raise awareness but also to make a tangible impact on the lives of children and adolescents battling rare diseases. Together we had a common goal: to accumulate as many "Fredis" as possible doing many physical activities, no matter which activity. The focus was just to keep on moving! 
 
Our collective effort demonstrated the strength of our team, as we gathered a total of 40.263 Fredis, securing the 11th position among all participants. Our commitment to corporate social responsibility and promoting well-being remains at the core of our identity. We are determined to explore more opportunities to support causes that align with our values and help us to make a difference in society.
 
#cordenpharma #teamwork #keepmoving #corporateresponsibility #KMSKchallenge #commitment #strongertogether

Download The CPHI Sustainability Report 2023 >Towards a
Greener Future, with contribution by William Cashin, Chief Quality & Compliance Officer. William Cashin asserts that collaboration needs to come from all stakeholders throughout the chain, including suppliers, customers, and government authorities.

“CordenPharma is focused on becoming more strategic about the energy and electricity we consume to produce our customers’ medicines that transform the lives of their patients. To that end, we encourage our suppliers
and customers to engage with us for increased science investment in order to produce more efficient processing steps that allow us to reduce/reuse the waste generated from these steps.

Global regulators can also play their part with supporting adoption ICH Q12 allowing lifecycle production process changes with low to moderate risk more easily than was the case in the past.

There are often good ideas at CDMO manufacturing sites on how to make the medicine more efficiently – after regulatory approval – which is stifled by customers unable or unwilling to face costly and time-consuming regulatory changes all over the world.”

Download the CPHI Sustainability Report 2023 here: https://lnkd.in/etdfrPf9

#CordenPharma #esg #sustainability #sustainablemanufacturing #greenbusiness #cdmo #sbti #pharmaceuticals #pharmaceuticalmanufacturing

The CordenPharma Team celebrates World Diabetes Day! Our contribution as a CDMO supports pharma & biotech innovators in the development and manufacture of life saving medicines for the successful treatment of diabetes, a disease that affects one in 10 adults worldwide.

Diabetes is a chronic condition that affects how your body processes glucose (sugar). There are different types of diabetes, with the most common being type 1 and type 2. 
While Insulin is essential for people with type 1 diabetes, it must be injected subcutaneously (under the skin) or administered via an insulin pump. Type 2 diabetes is characterized by insulin resistance. Several classes of oral antihyperglycemic agents are used to manage it like Metformin, which is a common first-line medication that improves insulin sensitivity, and Sulphonylureas, that stimulates the pancreas to produce more insulin. SGLT-2 inhibitors are a class of medicine used to lower high blood glucose levels.
GLP-1 analogues are well-established treatments for type 2 diabetes. They improve glycemic control through several mechanisms and have the added benefit of inducing weight loss without the risk of associated hypoglycemia. These molecules have also demonstrated favorable effects on obesity, NASH and on cardiovascular events, such as cardiovascular mortality, stroke, myocardial infarction, and albuminuria. 

CordenPharma’s expertise in manufacturing a wide range of technologies such as small molecules and peptide drug substance, paired with state-of-the-art Oral Solid Dosage and injectable capabilities, support our customers in the production of key medicines for diabetes already approved in the market or in ongoing clinical phase development.
 
www.worlddiabetesday.org

#worlddiabetesday #CordenPharma #cdmo #pharmaceutical #drugproducts #peptides #injectables #smallmolecules #oralsoliddose

Metric
Company Name	CordenPharma	biosyn Arzneimittel GmbH	P-BIO
Symbol
MSH ID	COM:CORDENPHARMA	DE:BIOSYN	ORG:P-BIO
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Pharmaceuticals	Biotechnology
Country	CH	DE	PT
Stage
Employee Count	1.41K
Website	cordenpharma.com	biosyn.de	p-bio.org
LinkedIn	corden-pharma-gmbh	biosyn-arzneimittel-gmbh	p-bio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	65.15
28-Day Growth Score	65.32
90-Day Growth Score	63.33
365-Day Growth Score	93.81

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CORDENPHARMA

CordenPharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue